NEW PUBLISHED STUDY CONFIRMS LONG-TERM EFFECT OF INSEA2® ON GLYCEMIC CONTROL.

RIMOUSKI (QUEBEC), February 12, 2019 - innoVactiv, a Canadian company dedicated to the development of science-based speciality ingredients, is pleased to announce the publication of its latest human clinical trial on its ingredient InSea2® in the peer-reviewed journal Phytotherapy Research.

The publication presents the results of a 6-month, randomized, double-blinded, placebo-controlled clinical trial involving 65 disglycemic subjects not using medication. Findings include significant reductions in glycated hemoglobin (HbA1c), fasting plasma glucose, post-prandial glucose and insulin-resistance index (HOMA-IR) compared with placebo, as well as normalization of glycemic status in 18.2% of treated subjects versus 0% in placebo group.

“We are thrilled about these new results, as they demonstrate the dramatic impact the use of InSea2® can have when taken on a daily basis. While all treated and placebo subjects followed the same strict diet and exercise regimen, researchers noticed a clear degradation of the glycemic condition in the placebo group, while two thirds of InSea2® subjects improved their glycemic status over the 6 months of the trial period”, said Jocelyn Bérubé, Executive Vice-President, Science and Regulatory Affairs for innoVactiv. “While our previous clinical studies have shown an immediate benefit of a single InSea2® intake on glycemic stress and brain acuity, these new results now clearly demonstrate the benefits of a daily use of InSea2® on glycemic health when taken over a longer period of time”, added Mr. Bérubé.

The published article can be found directly on the journal website, or through scientific index services such as Pubmed using the following reference:


Companies and formulators interested to hear more on these results can meet innoVactiv at upcoming Natural Product Expo West (Anaheim Convention Center, March 7-9, Booth #4771) and SupplySide East (Meadowlands Exposition Center, April 9-10, Booth B115) tradeshows.

About innoVactiv

innoVactiv’s mission is to develop and supply innovative health ingredients with scientific demonstrations of efficacy and safety for the nutraceutical and cosmeceutical industries. Its flagship ingredient InSea2® helps reduce the negative health impacts of added sugars by slowing digestive enzymes responsible for their assimilation.